Chen Schor - 24 Jan 2023 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Role: President & CEO, Director
Signature: /s/ Nick Harvey, Attorney-in-Fact
Issuer symbol: ACET
Transactions as of: 24 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 26 Jan 2023, 15:05:32 UTC
Previous filing: 14 Feb 2023
Next filing: 25 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACET	Common Stock	Award	$0	+85,500	+93%	$0.000000	176,969	24 Jan 2023	Direct	F1
holding	ACET	Common Stock						53,424	24 Jan 2023	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACET	Stock Option (Right to Buy)	Award	$0	+384,900		$0.000000	384,900	24 Jan 2023	Common Stock	384,900	$9.05	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2024. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.
F2	Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee.
F3	1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates.